Who are CAPEOX/Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate, Cellcept, Leustatin, Fudr, Cytarabine, Imuran.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capeox-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CAPEOX/Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAPEOX/Capecitabine (CAPEOX/Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; Fluoropyrimidine. Area: Oncology.

phase 3 Antimetabolite; Fluoropyrimidine Thymidylate synthase; DNA/RNA synthesis Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CAPEOX/Capecitabine (CAPEOX/Capecitabine) — Qilu Pharmaceutical Co., Ltd.. Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAPEOX/Capecitabine TARGET	CAPEOX/Capecitabine	Qilu Pharmaceutical Co., Ltd.	phase 3	Antimetabolite; Fluoropyrimidine	Thymidylate synthase; DNA/RNA synthesis
Mycophenolate	MYCOPHENOLIC ACID	Novartis	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	2004-01-01
Cellcept	MYCOPHENOLATE MOFETIL	Roche Palo	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	1995-01-01
Leustatin	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	marketed	Antimetabolite	DNA polymerase	1969-01-01
Imuran	AZATHIOPRINE	Legacy Pharma	marketed	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-11-23 — Leustatin · 10849919 · Method of Use · US
2039-08-16 — Cellcept · 12097284 · Formulation · US
2039-08-16 — Cellcept · 12226526 · Formulation · US
2039-08-16 — Cellcept · 11931455 · Formulation · US
2039-08-16 — Cellcept · 12194143 · Formulation · US
2039-08-16 — Cellcept · 12097285 · Formulation · US
2041-09-10 — Leustatin · 12539329 · Method of Use · US
2041-09-10 — Leustatin · 12533408 · Method of Use · US

Sponsor landscape (Antimetabolite; Fluoropyrimidine class)

Abramson Cancer Center at Penn Medicine · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAPEOX/Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/capeox-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab